Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867068 | 1.00 | POLB (0.46) | POLBHSP90AA1HSP90AB1CTSKKMT2A | |
| SCHEMBL1858809 | 0.90 | POLB (0.51) | POLBHSP90AA1HSP90AB1CTSKKMT2A | |
| SCHEMBL1869411 | 0.85 | CTSK (0.44) | POLBCTSKLMNASOAT2SOAT1 | |
| SCHEMBL1863235 | 0.85 | CTSK (0.44) | POLBCTSKLMNASOAT2SOAT1 | |
| SCHEMBL30516912 | 0.84 | POLB (0.51) | POLBHSP90AA1HSP90AB1CTSKKMT2A | |
| SCHEMBL13678948 | 0.84 | CTSK (0.42) | POLBHSP90AA1HSP90AB1CTSKKMT2A | |
| SCHEMBL12630078 | 0.83 | POLB (0.52) | POLBHSP90AA1HSP90AB1CTSKKMT2A | |
| SCHEMBL4138545 | 0.83 | KMT2A (0.48) | POLBHSP90AA1HSP90AB1CTSKKMT2A | |
| SCHEMBL4124902 | 0.79 | POLB (0.44) | POLBHSP90AA1HSP90AB1CTSKKMT2A | |
| SCHEMBL1861766 | 0.78 | KMT2A (0.51) | KMT2ASOAT2SOAT1HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3327/4885HSP90AA1 2488/4885HSP90AB1 2359/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | POLB 3349/4885HSP90AA1 2491/4885HSP90AB1 2369/4885 |
| US-20080188536-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3327/4885HSP90AA1 2488/4885HSP90AB1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.